| Systematic functional annotation of somatic mutations in cancer PKS Ng, J Li, KJ Jeong, S Shao, H Chen, YH Tsang, S Sengupta, Z Wang, ... Cancer cell 33 (3), 450-462. e10, 2018 | 285 | 2018 |
| Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling C Liu, H Lu, H Wang, A Loo, X Zhang, G Yang, C Kowal, S Delach, ... Clinical Cancer Research 27 (1), 342-354, 2021 | 141 | 2021 |
| Dual allosteric inhibition of SHP2 phosphatase M Fodor, E Price, P Wang, H Lu, A Argintaru, Z Chen, M Glick, HX Hao, ... ACS chemical biology 13 (3), 647-656, 2018 | 125 | 2018 |
| KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells KK Mahadevan, KM McAndrews, VS LeBleu, S Yang, H Lyu, B Li, ... Cancer Cell 41 (9), 1606-1620. e8, 2023 | 97 | 2023 |
| RET fusion as a novel driver of medullary thyroid carcinoma EG Grubbs, PKS Ng, J Bui, NL Busaidy, K Chen, JE Lee, X Lu, H Lu, ... The Journal of Clinical Endocrinology & Metabolism 100 (3), 788-793, 2015 | 89 | 2015 |
| SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors H Lu, C Liu, R Velazquez, H Wang, LM Dunkl, M Kazic-Legueux, ... Molecular cancer therapeutics 18 (7), 1323-1334, 2019 | 84 | 2019 |
| Functional annotation of rare gene aberration drivers of pancreatic cancer YH Tsang, T Dogruluk, PM Tedeschi, J Wardwell-Ozgo, H Lu, M Espitia, ... Nature communications 7 (1), 10500, 2016 | 70 | 2016 |
| Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers HX Hao, H Wang, C Liu, S Kovats, R Velazquez, H Lu, B Pant, M Shirley, ... Molecular cancer therapeutics 18 (12), 2368-2380, 2019 | 50 | 2019 |
| In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer CL Grzeskowiak, ST Kundu, X Mo, AA Ivanov, O Zagorodna, H Lu, ... Nature communications 9 (1), 2732, 2018 | 45 | 2018 |
| Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer H Lu, N Villafane, T Dogruluk, CL Grzeskowiak, K Kong, YH Tsang, ... Cancer research 77 (13), 3502-3512, 2017 | 45 | 2017 |
| Analyzing somatic genome rearrangements in human cancers by using whole-exome sequencing L Yang, MS Lee, H Lu, DY Oh, YJ Kim, D Park, G Park, X Ren, CA Bristow, ... The American Journal of Human Genetics 98 (5), 843-856, 2016 | 44 | 2016 |
| Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR H Lu, C Liu, H Huynh, TBU Le, MJ LaMarche, M Mohseni, JA Engelman, ... Oncotarget 11 (3), 265, 2020 | 34 | 2020 |
| Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression YH Tsang, Y Wang, K Kong, C Grzeskowiak, O Zagorodna, T Dogruluk, ... Elife 9, e48963, 2020 | 23 | 2020 |
| Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer J Dilly, MT Hoffman, L Abbassi, Z Li, F Paradiso, BD Parent, ... Cancer discovery 14 (11), 2135-2161, 2024 | 22 | 2024 |
| A functional genomic approach to actionable gene fusions for precision oncology J Li, H Lu, PKS Ng, A Pantazi, CKM Ip, KJ Jeong, B Amador, R Tran, ... Science advances 8 (6), eabm2382, 2022 | 22 | 2022 |
| Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1:: KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. MH Hofmann, H Lu, U Duenzinger, D Gerlach, F Trapani, AA Machado, ... Cancer Research 81 (13_Supplement), CT210-CT210, 2021 | 19 | 2021 |
| In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor F Savarese, A Gollner, D Rudolph, J Lipp, J Popow, MH Hofmann, ... Cancer Research 81 (13_Supplement), 1271-1271, 2021 | 17 | 2021 |
| Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance V Thatikonda, H Lu, S Jurado, K Kostyrko, CA Bristow, K Bosch, N Feng, ... bioRxiv, 2023 | 16 | 2023 |
| Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS … IC Waizenegger, H Lu, C Thamer, F Savarese, D Gerlach, D Rudolph, ... Cancer Res 82 (12_Supplement), 2667, 2022 | 10 | 2022 |
| Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination … KK Mahadevan, KM McAndrews, VS LeBleu, S Yang, H Lyu, B Li, ... bioRxiv, 2023.02. 15.528757, 2023 | 9 | 2023 |
